IRCT20090117001556N103招募中3 期
Resveratrol as adjunctive therapy in the treatment of negetive symptoms in patients with schizophrenia: a double blind and placebo controlled trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •Diagnosis of Schizophrenia based on DSM-5 criteria
- •Age between 18-60
- •Chronic Schizophrenia- duration of the disorder more than 2 years
- •Minimum score of 20 in negative sub score
- •being stable on risperidone( 4 to 6 mg per day) for the last 2 months
排除标准
- •Any serious medical or neurological problem
- •IQ less than 70.
- •Substance dependence during the last 6 months(except for nicotine and caffeine)
- •Score on HDRS less than 14
- •receiving ECT during the last 3 months
- •Acute or chronic systemic diseases
- •History of neurosurgery
- •History of head trauma
研究者
相似试验
招募中
3 期
Resveratrol in treatment of autismautistic disorder.Autistic disorderIRCT20090117001556N104Tehran University of Medical Sciences50
已完成
2 期
High dose Rosuvastatin as an adjunctive treatment in acute exacerbation of chronic obstructive pulmonary diseaseIRCT2016121020024N4Vice chancellor for research, Tehran University of Medical Sciences90
招募中
不适用
Cognitive therapy in the treatment of resistant social anxiety disorderSocial PhobiaRBR-7chtrjInstituto de Psiquiatria da UFRJ - IPUB
进行中（未招募）
1 期
Treatment of malignant melanoma with the combination of Vemurafenib, Cobimetinib, and Atezolizumab, including an integrated biomarker study: a phase II EADO trialPatients with hardly resectable/unresectable limited metastasis in malignant melanoma stages IIIC/IV (American Joint Committee on Cancer (AJCC) 2010) carrying the BRAF V600 mutation, in order to achieve operability.MedDRA version: 20.0Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001546-34-DEniversity Hospital Tübingen90
进行中（未招募）
1 期
eoadjuvant treatment with the combination of vemurafenib and cobimetinib (GDC-0973) in limited metastasis of malignant melanoma (AJCC stage IIIC/IV) and integrated biomarker study: a single armed phase II EADO trialPatients with metastatic melanoma, stage IIIC or IV (American Joint Committee on Cancer 2010) with hardly resectable/unresectable limited metastasis positive for the BRAF V600 mutation, which are expected to become resectable (R0) due to tumor shrinkage under vemurafenib + cobi-metinib.MedDRA version: 17.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001546-34-ATniversity Hospital Tübingen110